Phase II trial of ISIS-APOCIII Rx in patients with severely high triglyceride levels and familial chylomicronaemia syndrome

Trial Profile

Phase II trial of ISIS-APOCIII Rx in patients with severely high triglyceride levels and familial chylomicronaemia syndrome

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Dec 2014

At a glance

  • Drugs Volanesorsen (Primary)
  • Indications Hypertriglyceridaemia
  • Focus Therapeutic Use
  • Sponsors Isis Pharmaceuticals
  • Most Recent Events

    • 04 Dec 2014 Results published in the New England Journal of Medicine.
    • 04 Dec 2014 Status changed from active, no longer recruiting to completed, according to results published in NEJM.
    • 03 Dec 2014 According to an Isis Pharmaceuticals media release, results were published in the New England Journal of medicine.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top